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Case report
Mutations in the CHD7 gene, encoding for the chromodomain helicase DNA-
binding protein 7, are found in approximately 60% of individuals with CHARGE 
syndrome (coloboma, heart defects, choanal atresia, retarded growth and 
development, genital hypoplasia, ear abnormalities and/or hearing loss). Herein, 
we present a clinical case of a 14-year-old male presenting for evaluation of poor 
growth and pubertal delay highlighting the diagnostic challenges of CHARGE 
syndrome. The patient was born full term and underwent surgery at 5 days of life 
for bilateral choanal atresia. Developmental milestones were normally achieved. 
At age 14 his height and weight were -2.04 and -1.74 standard deviation score 
respectively. He had anosmia as well as prepubertal testes and micropenis (4 cm×1 
cm). The biological profile showed low basal serum testosterone and gonadotropins 
(testosterone, 0.2 nmol/L; luteinizing hormone, 0.5 U/L; follicle-stimulating 
hormone, 1.3 U/L), and otherwise normal pituitary function and normal imaging 
of the hypothalamic-pituitary area. The constellation of choanal atresia, anosmia, 
mild dysmorphic features, micropenis and delayed puberty were suggestive of 
CHARGE syndrome. Targeted genetic testing of CHD7 was performed revealing 
a de novo heterozygous CHD7 mutation (c.4234T>G [p.Tyr1412Asp]). Further 
paraclinical investigations confirmed CHARGE syndrome. Despite the presence 
of suggestive features, CHARGE syndrome remained undiagnosed in this patient 
until adolescence. Genetic testing helps clarify the phenotypic and genotypic 
spectrum to facilitate diagnosis, thus promoting optimal follow-up, treatment, and 
appropriate genetic counselling.
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Introduction
CHARGE syndrome (MIM 214800) is a rare genetic disorder characterized by a constella­
tion of several congenital anomalies (coloboma, heart defects, choanal atresia, retarded growth 
and development, genital hypoplasia, ear abnormalities and/or hearing loss). It was first 
described independently by Hall and Hittner in children with a combination of the hallmark 
congenital malformations.1) The acronym and initial diagnostic criteria for CHARGE 
Syndrome were introduced by Pagon in 1981.1,2) Currently, clinical diagnosis is based on the 
combined Blake (1998, revised in 2006)1) and Verloes' (2005) diagnostic criteria.3) 
It occurs in approximately 1:10,000 live births and incidence varies from one in 8,500 to 
15,000 depending on geographic region and clinical practices.2) Patients with CHARGE 
syndrome exhibit a broad and variable clinical presentation.4) The molecular basis of 
CHARGE syndrome was first described in 2004 by Vissers and colleagues. Mutations 
in CHD7 encoding of the chromodomain helicase DNA­binding protein 7, an ATP­
dependent chromatin remodeler have been demonstrated to be the major genetic cause of 
CHARGE syndrome, underlying approximately 60% of cases.4) The mutational spectrum is 
predominantly characterized by heterozygous single­nucleotide variants affecting protein 
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function (44% nonsense, 34% frameshift, 11% splice site, and 
8% missense).5) Whole­exon deletions or microdeletions of 
8q12.1 (the chromosomal band including CHD7), are found in 
less than 5% of cases5) Notably, almost all CHARGE syndrome 
patients are sporadic cases, yet a few familial cases have been 
documented.6) No clear genotype­phenotype correlation exists.7) 
We present the diagnostic challenges of CHARGE syndrome 
using the clinical case of a male adolescent presenting with 
delayed puberty in which genetic testing revealed a novel 
causative mutation in CHD7.  
Case report
A 14­year­old Caucasian male presented for endocrine 
evaluation of poor growth and pubertal delay. He was the 
youngest of three children born to a nonconsanguineous 
couple. The family history was notable for delayed puberty in 
both parents. The mother reported having menarche at age 
of 15 while the father indicated he developed later than his 
peers having experienced his growth spurt at approximately 
age of 16. The mother received fertility treatment for her first 
pregnancy, yet subsequently conceived twice spontaneously 
with uneventful pregnancies and deliveries. The parents were 
otherwise healthy, with normal height (father: +1.08 standard 
deviation score [SDS], mother: +0.21 SDS) and no dysmorphic 
features. The patient was born at 41 weeks gestation (birth 
weight 3,350 g (­0.13 SDS); length 50 cm (­0.05 SDS); Apgar 
scores: 8/8/8). Bilateral choanal atresia was suspected clinically 
in the first days of life and mixed (fibrotic and osseous) choanal 
atresia (predominantly fibrotic) was confirmed via computed 
tomography (CT) imaging (Fig. 1). Endoscopic laser surgery 
was performed at 5 days of life with serial surgical interventions 
at 1 month and 3.5 months. Panendoscopy did not reveal any 
additional anomalies and ultrasound revealed normal urinary 
tract structures without visceral malformation. He achieved 
global developmental milestones within expected timeframes 
yet he did not begin walking until 18 months. Interestingly, 
the parents retrospectively reported that he often appeared to 
struggle with balance during infancy. At 3.8 years he underwent 
unilateral surgical repair of an inguinal hernia. His medical 
history was otherwise unremarkable. He reported a reduced 
sense of smell that had never been formally investigated. 
Pubarche was noted at age of 13. Charting his growth did not 
reveal any deflection as both height and weight parameters were 
between ­1.5 and ­2 SDS since the age of 5. 
In the first visit in our clinic at 13.5 years, his height (Holter 
Stadiometer) was 139.9 cm (­2.04 SDS) and weight was 30.0 kg 
(­1.74 SDS). He exhibited normal segmental proportions (arm 
span: 138 cm, upper versus lower segment: 0 SDS). Clinical 
evaluation revealed a left low­set ear with helix anteversion 
and an ogival palate (with presence of a dental apparatus). The 
patient was unvirilized with Tanner A1 P2 G1 with prepubertal 
Fig. 1. Axial computed tomography scan at day 3 of life at the reference level of 
the pterygoid plates, showing bilateral choanal atresia (arrows).
Table 1. Laboratory testing
Variable At age 14 years Reference values
Inhibin-B (pg/mL) 86.4 35–182 (G1)
AMH (pmol/L) 443.6 5–800
LHRH stimulation test (U/L)
  LH basal 0.5 0.5–2.5 (G1)
  LH max 8.3 <5.0 (G1)
  FSH basal 1.3 <3.0 (G1)
  FSH max 4.4 -
Testosterone (nmol/L) 0.2 0.1–1.0 (G1)
17-OH-progesterone (nmol/L) 1.0 <3.0
Androstenedione-D4 (nmol/L) 0.8 1.54±0.15
DHEAS (µmol/L) 3.4 1.88±1.25
Prolactin (µg/L) 9.2 <20
TSH (mU/L) 1.39 0.5–4.5
T4 libre (pmol/L) 15 9–25
IGF-1 (µg/L) 225 99–547
IGFBP3 (mg/L) 5.2 2.2–8.3
ACTH (pg/mL) 21 10–60
Cortisol (random) (nmol/L) 413 100–600
Hemoglobin (g/L) 131 117–157
Hematocrit (%) 38 35–47
Ferritin (µg/L) 41 20–120
Total calcium (mmol/L) 2.37 2.15–2.55
Phosphate (mmol/L) 1.41 1.0–1.5
Alkaline phosphatase (U/L) 231 110–370
25-(OH)-vitamin D3 (µg/L) 25.5 8.4–52.3
G1, Tanner genital stage I; AMH, anti­Müllerian hormone; 
LHRH, luteinizing hormone­releasing hormone; LH, luteinizing 
hormone;  FSH,  fo l l ic le ­st imulat ing hormone;  DHEAS, 
dehydroepiandrosterone sulfate; TSH, thyroid­stimulating 
hormone; IGF­1, insulin growth factor­1; IGFBP3, insulin growth 
factor binding protein 3; ACTH, adrenocorticotropic hormone.
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testes (2 mL bilaterally by Prader orchidometer) and micropenis 
(4 cm×1 cm; reference range, 5.5–12.8 cm8)).
At 14 years, growth velocity was slow at 3.1 cm/yr (­2 
SDS) and  bone age was  delayed by 2.5 years compared 
to chronological age, consistent with his lack of pubertal 
development. Formal smell testing ("Burghart Sniffin' Sticks 
Identification Test 16") confirmed anosmia (score 5/16, <5th 
percentile). Basal serum hormone profiling indicated pre­
pubertal serum testosterone (0.2 nmol/L [0.1–1.0 {T1} via liquid 
chromatography mass spectroscopy, LC­MS/MS]) in the setting 
of low gonadotropins (LH: 0.5 U/L [0.5–2.5 {G1}]), FSH: 1.3 U/
L (<3 [G1]) via the Cobas 6000 (Roche Diagnostics, Rotkreuz, 
Switzerland) using electrochemiluminescence immunoassay. 
Normal basal hormonal levels suggested intact thyrotrope, 
corticotrope and somatotrope axes (Table 1). Sertoli­cell 
function, as assessed by AMH (443.6 pmol/L [5–800 pmol/L]) 
and Inhibin B (86.4 pg/mL [35–182 pg/mL]), was normal for his 
prepubertal stage. There was no evidence of any chronic disease 
or functional causes for his hypogonadotrophic hypogonadism 
(Table 1).  
The constellation of choanal atresia, anosmia, mild dysmor­
phic features, micropenis and delayed puberty were suggestive 
of CHARGE syndrome. After obtaining informed consent 
from the patient and his family, Sanger sequencing was 
Tyr1412Asp
Fig. 2. (A) The schematic representation of CHD7 protein and the location of mutation Tyr1412Asp. The functional domains are indicated in the schema. 
(B) The structural modeling of chromodomains and helicase domains of CHD7 and the location of Try1412Asp.  Tyr residue at position 1412 is located in 
the core of the helicase C domain. The change to an Asp is predicted to have a major detrimental effect on the structural stability of CHD7 as a large buried 
hydrophobic amino acid is replaced by a small charged hydrophilic one.
(A) (B)
(C) (D)
Fig. 3. (A-D) Imaging studies showing midline and intraauricular malformations. (A) Magnetic resonance 
imaging (MRI) (axial T1 with gadolinium) at 14 years of age, showing hypoplastic lateral and posterior 
semicircular canals (long arrows) and dysplastic vestibule (short arrow). (B) MRI at 14 years of age, showing 
Mondini dysplasia of the partition of the cochlea. (C) MRI at 14 years of age, showing decreased anterior 
pituitary volume (160 mm3). (D) MRI at 14 years of age, showing olfactory bulb aplasia (R) and hypoplasia (L).
R, right; L, left.
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performed on DNA extracted from peripheral blood. The 
patient was found to harbor a heterozygous CHD7 mutation 
(c.4234T>G [p.Tyr1412Asp]). This is a private variant, not 
seen in large control databases such as the 1,000 Genomes 
or ExAC. Structural modelling revealed that the Tyr residue 
at position 1412 is located in the core of  the helicase C 
domain, and the change to an Asp is predicted to have a major 
detrimental effect on the structural stability of CHD7 as a 
large buried hydrophobic amino acid is replaced by a small 
charged hydrophilic one (Fig. 2). This variant is predicted to be 
deleterious by both sorting intolerant from tolerant­Algorithm 
and PolyPhen­2. The mutation was not detected in his parents, 
and is therefore a de novo mutation. Subsequent cranial 
magnetic resonance imaging (MRI) showed abnormal lateral 
and posterior semicircular canals (Fig. 3A) with vestibular and 
cochlear malformation (Fig. 3B). Additional findings included 
a verticalized sella turcica, a decreased hypophyseal volume 
(160 mm3) for his age (Fig. 3C), hypoplastic gyri, deformed left 
VII cranial nerve, right olfactive bulb aplasia and left olfactive 
bulb hypoplasia (Fig. 3D). Echocardiography did not reveal 
any cardiac malformation and echocardiogram was normal. 
The ophthalmologic investigation was within normal limits, 
notably without coloboma. Vestibular function assessment 
showed normal utricular (subjective vertical testing and ocular 
vestibular­evoked myogenic potential [VEMP] test) and 
saccular function (cervical­VEMP). The video head impulse test 
used to identify peripheral vestibular deficits revealed posterior 
and lateral semicircular canal dysfunctions on both sides, 
consistent with the anomalies found on the MRI. Audiometry 
was normal. Luteinizing hormone­releasing hormone 
stimulation testing (Table 1) triggered only minor increase in 
LH and FSH (8.3 mU/L and 4.4 mU/L, respectively, LH:FSH 
ratio 1.88). Bone densitometry via dual X­ray absorptiometry 
(Lunar iDXA­210430) showed normal bone density for his 
bone age (Lumbar spine z­score: ­1.7 SDS) according to the 
International Society for Clinical Densitometry references. No 
neuropsychological evaluation was performed as our patient 
followed normal educational track without notable difficulty.
Based on these findings and the Verloes' 2005 Criteria,3) the 
patient was diagnosed with CHARGE syndrome. Specifically, 
he exhibited 2 major criteria (choanal atresia and hypoplastic 
semicircular canals) and 2 minor criteria (hypothalamo­
hypophyseal dysfunction/gonadotropin deficiency and abnor­
mal external/middle ear) (Table 2). Low dose testosterone (50 
mg via intramuscular injection monthly) was initiated at 14.6 
years and improved growth velocity (from 3 to 9 cm/yr) and 
development of secondary sexual characteristics. No significant 
testicular enlargement was observed during this treatment and 
pubertal induction is ongoing.
Discussion
The combination of choanal atresia, anosmia, mild non­
specific dysmorphia, micropenis and pubertal delay in our 
patient suggested CHARGE syndrome. Genetic testing led to 
the identification of a de novo CHD7 mutation (p.Tyr1412Asp). 
Indeed, according to current genetic guidelines,9) several 
lines of evidence support that the identified CHD7 variant 
is pathogenic: (1) it is a private variant, i.e., not seen in the 
general population;10) (2) it is located in a critical functional 
domain of CHD7 and is predicted to be deleterious by multiple 
computational tools; and (3) the de novo nature of this mutation 
is consistent with the absence of family history of CHARGE­
like features, while a heterozygous mutation is coherent with the 
autosomal dominant inheritance of CHARGE syndrome. This 
finding is concordant to other studies showing a high incidence 
of de novo changes in CHARGE syndrome.6) The presence of 
a CHD7 gene mutation triggered further investigation that 
subsequently revealed additional clinical features and ultimately 
enabled the diagnosis of CHARGE syndrome. 
During neonatal life, the patient’s choanal atresia had been 
considered an isolated congenital malformation, and thus 
Table 2. Diagnostic criteria (Verloes-20053)) observed in the patient
Diagnostic criteria (Verloes 2005)
Major criteria Patient
  Coloboma (iris or choroid, with/without microphthalmia) No
  Choanal atresia Yes
  Hypoplastic semicircular canals Yes
Minor criteria
  Rhombencephalic dysfunction (brainstem dysfunctions, cranial nerve VII-XII palsies, and neurosensory deafness) No
  Hypothalamo-hypophyseal dysfunction (including GH and gonadotrophin deficiencies) Yes
  Abnormal middle or external ear Yes
  Malformation of mediastinal organs (heart, esophagus) No
  Mental retardation No
Diagnostic criteria interpretation
  Typical CHARGE: 3 major, or 2 major and 2 minor criteria Yes
  Partial/incomplete CHARGE: 2 major and 1 minor criteria No
  Atypical CHARGE: 2 major, or 1 major and 3 minor criteria No
CHARGE: coloboma, heart defects, choanal atresia, retarded growth and development, genital hypoplasia, ear abnormalities and/or 
hearing loss; GH, growth hormone.
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further clinical and molecular investigations were not pursued. 
Consequently, CHARGE syndrome remained undiagnosed 
until adolescence. As with other syndromes with variable 
clinical presentation and several hallmark features, the initial 
diagnosis hinges on the awareness of the constellation of critical 
features, followed by careful clinical assessment. Choanal 
atresia is associated with other congenital malformations in 
approximately half of cases.11) Further, a study by Burrow et 
al.12) observed that CHARGE syndrome was diagnosed in 
26% of patients with choanal atresia, and associated anomalies 
were more frequent in patients with bilateral choanal atresia. 
Similarly, the study by Kim et al.13) found that CHARGE 
syndrome accounted for 4 of 27 cases (15%) of choanal atresia, 
yet was more frequent in patients with bilateral cases (4 of 14, 
31%). Mutations in the CHD7 gene should therefore be tested 
in all newborns presenting with bilateral choanal atresia to 
facilitate early detection of CHARGE cases.
The vast phenotypic spectrum of CHARGE syndrome 
and the variable presentation in patients carrying presumed 
pathogenic CHD7 mutations have recently raised the debate of 
whether CHARGE syndrome should be considered a clinical 
diagnosis, a molecular diagnosis, or both.7,14) In a recent study by 
Bergman and colleagues, 18 of 131 (14%) and 22 of 124 (17%) of 
patients harboring a mutation in CHD7 could not be clinically 
diagnosed with CHARGE syndrome based on the Blake’s and 
Verloes' diagnostic criteria, respectively. The authors proposed 
that CHD7 analysis should not be solely restricted to patients 
fulfilling current diagnostic criteria. The authors suggested 
that CHD7 analysis could be considered in the presence of any 
cardinal features, rather than limiting it to the 3 cardinal features; 
coloboma, choanal atresia, semicircular canal hypoplasia. 
Further, the presence of CHARGE syndrome features in a family 
member could also be a potentially suggestive feature.7) Hale et 
al.14) recently proposed new diagnostic criteria for CHARGE 
syndrome diagnosis by expanding the list of minor features and 
including CHD7 gene mutation as a major diagnostic criterion. 
Notably, 17% of patients with a CHD7 mutation do not meet 
current diagnostic criteria for CHARGE.6) Accordingly, some 
have recommended CHD7 analysis in cases of  suspected 
CHARGE syndrome, i.e., patients who do not meet current 
diagnostic criteria.6) Considering the present case, a high 
clinical suspicion and thorough clinical evaluation combined 
with genetic testing enabled an accurate diagnosis. Notably, 
the strict adherence to the Hale criteria would have potentially 
led to earlier diagnosis in the present case. In our patient, 
neonatal diagnosis of CHARGE syndrome could have led to 
the evaluation of the central activation of the gonadotropic axis 
during minipuberty (2–3 months of life), and subsequently 
earlier intervention during adolescence in order to induce 
secondary sexual charac teristic development concurrently with 
his peers. 
The diagnosis of CHARGE syndrome may lead to an early 
treatment strategy of testosterone replacement aimed to restore 
a normal sex steroid milieu. This treatment might be switched 
to exogenous gonadotropin therapy or pulsatile GnRH therapy 
in case of continuous deficient secretion of gonadotropins or 
absence of reversal.15) Pubertal delay and hypogonadotropic 
hypogonadism are common in patients with CHARGE synd­
rome. Indeed, hypogonadotropic hypogonadism occurs in 
nearly two­thirds of patients harboring CHD7 mutations.16) 
Conversely, CHD7 mutations are found in 5%–8% of patients 
diagnosed with Kallmann syndrome (KS).2,17,18) Jongmans et 
al.17) have proposed CHD7 sequencing in KS patients if one 
or more additional CHARGE syndrome features are present. 
Missense mutations are more prevalent in KS and are mostly 
transmitted through mildly affected fertile probands. Therefore, 
clinical and molecular assessment of family members may help 
expand the phenotypic and genotypic spectrum of CHARGE 
syndrome. Reversal of hypogonadic hypogonadism has been 
observed even in patients with a truncating mutation in the 
CHD7.19)
Whether the patient has constitutional delayed of puberty 
or congenital hypogonadotropic hypogonadism, the treatment 
remains the same in adolescence presentation.20) Due to the 
possibility of spontaneous activation of the gonadal axis, 
pubertal induction with low doses of  testosterone seems 
reasonable. However, in cases of confirmed congenital hypogo­
nadotropic hypogonadism, gonadotropin therapy is also a 
plausible treatment strategy and has the added benefit of 
inducing testicular growth and fertility potential.18) 
In conclusion, we present a novel CHD7 mutation in a 
patient with a typical CHARGE syndrome (according to 
Verloes' diagnostic criteria) who remained undiagnosed until 
adolescence. The late detection was likely due to the lack 
of other signs/symptoms typically observed in CHARGE 
syndrome such as coloboma, hearing loss, and facial palsy.
Due to the benefits of prompt diagnosis and required follow­
up of these patients, we recommend genetic testing in suspected 
cases which do not fulfill the complete clinical diagnostic 
criteria. Genetic testing promotes understanding of CHARGE 
syndrome development and clinical presentation, and may 
promote prompt diagnosis and thus timelier clinical care and 
access to genetic counselling. 
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